Consensus Vertex Pharmaceuticals Incorporated Sao Paulo

Stocks

VRTX34

BRVRTXBDR001

Pharmaceuticals

Delayed Sao Paulo 15:29:53 2026-09-29 EDT			5-day change	1st Jan Change
85.86 ^BRL	-0.42%		+3.90%	+9.74%

09-28	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT

7e745f46d1c535e33b9311fe015.GpcjDZ3zVbUgJsjE_icTxfELXGNxGz70DwuGp7fzT0A.LtF1d6vLDYZOc4Lyqn5LnaN4Lxk6Ik-yWVHcwc2efS5X8llB7qkBwUdFuw~528c613e56dc88b8bf233fc3f3d5667b

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

09-28	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
09-23	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
08-11	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
08-05	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
08-04	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
08-04	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
08-04	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
08-04	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
08-04	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
08-04	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
08-04	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
08-04	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
08-04	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
07-21	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
07-20	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
07-13	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
07-09	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
07-08	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT
07-07	Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says	MT
07-07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $570 From $543, Maintains Outperform Rating	MT
07-07	Baird Adjusts Price Target on Vertex Pharmaceuticals to $350 From $330	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+12.17%
	JOHNSON & JOHNSON					+4.37%
	ABBVIE INC.					+5.91%
	MERCK & CO., INC.					+4.29%
	ROCHE HOLDING AG					+7.46%
	NOVARTIS AG					+5.11%
	ASTRAZENECA PLC					+28.35%
	AMGEN INC.					-7.72%
	GILEAD SCIENCES, INC.					+4.87%
	Average					+7.20%
	Weighted average by Cap.					+7.93%